BPC-157

Overview

BPC-157 is a synthetic peptide made of 15 amino acids with the sequence GEPPPGKPADDAGLV. Its name stands for "body protection compound," and it was described as a partial sequence of a larger protein reported in human gastric juice (Chang 2011). Researchers have noted that it is unusually stable in gastric juice for a peptide, which is why many animal studies gave it by mouth as well as by injection.

It has been studied in animal models of stomach and gut injury, tendon and ligament damage, muscle and bone injury, and several toxicity models. The overall picture is a large preclinical literature, most of it from a single laboratory, and almost no controlled human data. A 2025 systematic review found 35 preclinical studies and one clinical study relevant to musculoskeletal outcomes, all at the lowest levels of the evidence hierarchy (Vasireddi 2025).

For a longer walkthrough of individual studies and the gap between online claims and the published record, see our article on BPC-157 research evidence.

Research history

BPC-157 comes out of the Department of Pharmacology at the University of Zagreb in Croatia, where Predrag Sikiric, Sven Seiwerth and many collaborators have published on it since the early 1990s. Their early work focused on the stomach and intestine, and the group then tested the peptide in one tissue model after another.

A pharmaceutical company developed the molecule under the codes PL 14736 and PLD-116 for inflammatory bowel disease, and a 2003 paper described it as being in clinical trials at the time (Staresinic 2003). Full peer-reviewed results from that program were not published in a form that settles any clinical question.

The Zagreb group's own reviews argue that BPC-157 was effective across gastrointestinal injury models and improved tendon, ligament and bone healing in rodents (Seiwerth 2018). These are summaries by the originating lab of its own program. Independent groups in Taiwan and China began publishing on the peptide in the 2010s and 2020s, and human reports appeared only from 2021 onward.

What published studies have examined

Cell studies

A Chang Gung University group in Taiwan studied tendon fibroblasts from rat Achilles tendons (Chang 2011). BPC-157 did not directly increase cell proliferation, but it increased outgrowth of cells from tendon explants, improved survival under oxidative stress and increased migration, which the authors linked to FAK and paxillin signaling. It is one of the more cited examples of a lab outside Zagreb reporting a mechanism.

Animal studies

In a representative Zagreb study, rats with a surgically cut Achilles tendon given BPC-157 showed better function scores, higher load to failure and more organized collagen over two weeks than saline controls (Staresinic 2003). Reviews describe proposed mechanisms involving VEGF receptor 2, nitric oxide signaling through Akt and eNOS, and ERK1/2, all observed in rodent tissue or cultured cells (McGuire 2025).

A group at the Air Force Medical University in Xi'an, developing BPC-157 as a potential wound-healing drug, reported pharmacokinetics in rats and beagle dogs (He 2022). The intact peptide had an elimination half-life under 30 minutes and was broken down into smaller fragments and amino acids, cleared mainly through urine and bile.

Human reports

Only three small human reports exist, all from one lead author in private practice and none with a control group (McGuire 2025). A retrospective chart review of 16 people with knee pain relied on phone follow-up months later (Lee 2021). A pilot in 12 women with interstitial cystitis used a self-reported global response questionnaire with no placebo arm (Lee 2024). A third report described two adults in an intravenous safety pilot.

Open questions

• Replication. Most positive findings come from one research group. Independent confirmation of the core injury results is limited.
• Human efficacy. No randomized, placebo-controlled trial of BPC-157 for any musculoskeletal or gastrointestinal outcome has been published.
• Human safety. The 2025 systematic review found no clinical safety data in its search window (Vasireddi 2025). Animal safety studies do not establish human safety, and the FDA has cited immunogenicity and impurity concerns.
• Mechanism. No specific receptor has been identified. A long list of proposed pathways may reflect broad effects or simply the absence of a defined target.
• Material quality. Products sold outside regulated channels vary in identity and purity, which also affects how any study using them can be interpreted. Our guide to reading a certificate of analysis covers what to check.